Uberti Elza Maria Hartmann, Fajardo Maria do Carmo, Ferreira Silvia Villa Verde Ribeiro, Pereira Maurício Vannoni, Seger Raquel Cristina, Moreira Maria Amélia Rolla, Torres Magali Duarte, de Nápoli Gilberto, Schmid Helena
TDC of CHSCPA, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.
Gynecol Oncol. 2009 Dec;115(3):476-81. doi: 10.1016/j.ygyno.2009.09.012. Epub 2009 Oct 8.
To evaluate whether prophylactic chemotherapy (P-chem) with one bolus dose of actinomycin D (Act-D) during the uterine evacuation of patients with high-risk hydatidiform mole (Hr-HM) affects reproductive outcomes in subsequent pregnancies.
From 1987 to 2006, 1090 patients with gestational trophoblastic disease (GTD) were evaluated at a Trophoblastic Disease Center in southern Brazil; 265 with Hr-HM were selected and retrospectively analyzed. From 1996 to 2006, 163 received one bolus dose of Act-D at the time of uterine evacuation (Hr-HM-chem group); 102 with the same risk factors did not get P-chem (Hr-HM-control group). In March 2009, the number of pregnancies, progression of first pregnancy, and association of low age and low parity with subsequent pregnancy were evaluated.
The percentage of patients that became pregnant was similar in both groups (Hr-HM-control: 59.5%; Hr-HM-chem group: 45.7%; p=0.069) and independent of HM progression. Percentages of no pregnancies because of age (> or =40 years) or hysterectomy were also similar. Type of subsequent pregnancy was not statistically different between groups, and the rate of live births associated with pregnancies for which US showed a live fetus was high. Frequency of repeat GTD was unexpectedly high in both groups (4.2% and 6.3%; p=1.00).
P-chem did not affect reproductive outcomes for patients with Hr-HM. Patients allowed to become pregnant again in both groups had high rates of live births associated with normal pregnancies. Chances of a subsequent pregnancy were higher in the low age and low parity subgroups.
评估在高危葡萄胎(Hr-HM)患者清宫时给予单剂量放线菌素D(Act-D)进行预防性化疗(P-chem)是否会影响其后续妊娠的生殖结局。
1987年至2006年期间,巴西南部的一个滋养细胞疾病中心对1090例妊娠滋养细胞疾病(GTD)患者进行了评估;选取其中265例Hr-HM患者进行回顾性分析。1996年至2006年期间,163例患者在清宫时接受了单剂量Act-D(Hr-HM-化疗组);102例具有相同危险因素的患者未接受P-chem(Hr-HM-对照组)。2009年3月,评估了妊娠次数、首次妊娠进展情况以及低年龄和低产次与后续妊娠的相关性。
两组患者的妊娠率相似(Hr-HM-对照组:59.5%;Hr-HM-化疗组:45.7%;p = 0.069),且与葡萄胎进展无关。因年龄(≥40岁)或子宫切除而未妊娠的比例也相似。两组后续妊娠类型无统计学差异,超声显示有活胎的妊娠活产率较高。两组中复发性GTD的发生率均意外地高(4.2%和6.3%;p = 1.00)。
P-chem对Hr-HM患者的生殖结局无影响。两组中再次妊娠的患者正常妊娠活产率均较高。低年龄和低产次亚组后续妊娠的机会更高。